Iwamoto, H.; Shimose, S.; Noda, Y.; Shirono, T.; Niizeki, T.; Nakano, M.; Okamura, S.; Kamachi, N.; Suzuki, H.; Sakai, M.;
et al. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers 2021, 13, 2786.
https://doi.org/10.3390/cancers13112786
AMA Style
Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M,
et al. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers. 2021; 13(11):2786.
https://doi.org/10.3390/cancers13112786
Chicago/Turabian Style
Iwamoto, Hideki, Shigeo Shimose, Yu Noda, Tomotake Shirono, Takashi Niizeki, Masahito Nakano, Shusuke Okamura, Naoki Kamachi, Hiroyuki Suzuki, Miwa Sakai,
and et al. 2021. "Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice" Cancers 13, no. 11: 2786.
https://doi.org/10.3390/cancers13112786
APA Style
Iwamoto, H., Shimose, S., Noda, Y., Shirono, T., Niizeki, T., Nakano, M., Okamura, S., Kamachi, N., Suzuki, H., Sakai, M., Kajiwara, A., Itano, S., Tanaka, M., Yamaguchi, T., Kuromatsu, R., Koga, H., Torimura, T., & on behalf of The Kurume Liver Cancer Study Group of Japan.
(2021). Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 13(11), 2786.
https://doi.org/10.3390/cancers13112786